Retatrutide: Dosage & Administration
Part of the Retatrutide Complete Guide
Research Peptides
Advertiser link — we may earn a commission at no extra cost to you.
Investigational Status (Important Context)
Retatrutide (LY3437943) is Eli Lilly's once-weekly triple agonist of GLP-1, GIP, and glucagon receptors — one of the most aggressively developed obesity drugs of the 2020s. It is not FDA-approved as of 2026. Phase 3 development is ongoing under the TRIUMPH program (obesity) and Phase 3 cardiovascular outcomes trials are running in parallel.[3]
The dosing information below comes from Phase 2 trials published in 2023 in The New England Journal of Medicine (obesity) and The Lancet (type 2 diabetes).[1][2] Clinical-grade retatrutide is not commercially available — Lilly distributes it only within clinical trials. Retatrutide sold in "research peptide" markets is unregulated and is not the clinical-grade molecule used in Lilly trials; identity, dose accuracy, and quality cannot be verified without independent lab testing.
Retatrutide is not on the July 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list agenda.
Phase 2 Trial Doses & Outcomes
The pivotal Phase 2 obesity trial (Jastreboff et al., NEJM 2023) randomized 338 adults with obesity to retatrutide 1 mg, 4 mg, 8 mg, or 12 mg weekly, or placebo, for 48 weeks.[1]
| Dose | Mean weight loss (48 wks) | ≥20% weight loss | Heart rate Δ | Notes |
|---|---|---|---|---|
| 1 mg | ~7.2% | 13% | +2 bpm | Sub-therapeutic — likely titration dose only in Phase 3 |
| 4 mg | ~17.1% | 40% | +4 bpm | Comparable to high-dose semaglutide |
| 8 mg | ~22.8% | 60% | +6 bpm | Comparable to highest-dose tirzepatide |
| 12 mg | ~24.2% | 63% | +7 bpm | Highest mean weight loss ever recorded in an obesity trial; curve had not plateaued at 48 weeks |
The 8 mg and 12 mg doses are the most likely Phase 3 maintenance targets. The 12 mg group's weight loss curve was still declining at 48 weeks, suggesting longer treatment could produce even greater results.
Phase 2 Titration Schedule
Retatrutide requires substantial titration to manage class-typical GI side effects. The Phase 2 obesity trial used the following 4-week-step pattern to reach maintenance doses:
| Target dose | Weeks 1–4 | Weeks 5–8 | Weeks 9–12 | Weeks 13–16 | Weeks 17+ |
|---|---|---|---|---|---|
| 4 mg | 2 mg | 4 mg | 4 mg | 4 mg | 4 mg |
| 8 mg | 2 mg | 4 mg | 8 mg | 8 mg | 8 mg |
| 12 mg | 2 mg | 4 mg | 8 mg | 12 mg | 12 mg |
Total time to reach the 12 mg target: 13 weeks (~3 months) of escalating weekly doses. Each step is 4 weeks rather than 1 week (as with semaglutide / tirzepatide) — retatrutide produces more pronounced GI burden than pure GLP-1s due to its added GIP + glucagon activity. If a step is not tolerated, hold at the current dose for an additional 4 weeks before advancing.
Administration
- Route: subcutaneous injection — Lilly clinical formulation is a pre-filled auto-injector pen.
- Sites: abdomen, thigh, or upper arm. Rotate sites weekly.
- Timing: any day of the week; same day each week for consistent intervals. Any time of day.
- With or without food: not strictly dependent.
- Missed dose: if within 4 days of scheduled day, take as soon as possible and resume normal schedule. If > 4 days late, skip and resume next scheduled dose. Do not double-dose.
- Extended interruption (> 3 weeks without a dose): GLP-1 receptor tolerance degrades; restart at a lower dose and re-titrate rather than resume at previous maintenance.
See the injection technique guide for general SC technique.
Drug-Interaction Timing
Retatrutide has the strongest gastric-emptying delay of any peptide on this site due to its triple-agonist mechanism. Affects oral medication absorption:
- Oral contraceptives: reduced absorption is plausible. Consider backup contraception during titration.
- Levothyroxine: separate by ≥30 minutes; monitor TSH after starting and at dose increases.
- Warfarin: monitor INR more frequently during dose changes.
- Narrow-therapeutic-index drugs (digoxin, lithium, anticonvulsants, immunosuppressants): monitor levels closely.
- Insulin / sulfonylureas: reduce dose substantially to avoid hypoglycemia, especially during titration in diabetic patients. Retatrutide's glucagon component complicates glucose handling.
- Other GLP-1 family drugs (semaglutide, tirzepatide, survodutide, mazdutide, liraglutide): do not combine.
Duration & Long-Term Use
Long-term continuous use is the anticipated maintenance pattern, consistent with the GLP-1 class. Phase 2 trial durations were 48 weeks. Phase 3 trials extend to 72 weeks and beyond. Weight regain after discontinuation is expected.
- No cycling required — retatrutide does not produce receptor tolerance the way some peptides do.
- Continuous use is the post-approval anticipated pattern.
- Long-term cardiovascular safety is the open question that Phase 3 cardiovascular outcomes trials will answer.
Storage
- Pre-filled clinical pens: refrigerate at 2–8°C until first use.
- After first use: per pen instructions — typically room temperature up to 30°C for up to 28–30 days.
- Do not freeze.
- Protect from light.
- Travel: insulated cooler with ice pack. Avoid direct contact with frozen gel packs.
For broader storage rules, see the peptide storage guide.